3 models fit Vertex Pharmaceuticals Incorporated Common Stock and they disagree: 1 of 3 land within 15% of the average. The price is above every model.
Two or more of our models back this value.
Large premium(i)Bronze55
Valued as a growth company: Discounted cash flow, P/E comparison, and EV/EBITDA comparison.
ACCE opinionVertex Pharmaceuticals Incorporated Common Stock (VRTX)
Fair value (3 models)
$327
ACCE price target
$503
Rating
Overvalued
Horizon
12 months
Fair value published on 19 Oct 2026, 18:04 CEST; previously $492 since 11 Oct 2026, 00:00 CEST.
ACCE price target published on 19 Apr 2026, 00:00 CEST.
Rating published on 19 Oct 2026, 18:04 CEST.
Price used: $524 at the close on 23 Oct 2026, 22:00 CEST.
Models: Discounted cash flow, P/E comparison, and EV/EBITDA comparison.
Fair value: the average of the applicable valuation models (discounted cash flow, multiples, residual income, dividend discount, shareholder yield), each run on the latest financial statements and the market price shown. Opinion columns (fair value, target, rating) are shown apart from the data. Full methodology: acceinvestments.com/data/how-we-value-stocks
Conflicts of interest: The author holds no personal position in this security. General statement
Produced by ACCE Investments (acceinvestments.com)
Data
Price vs fair value
60.1% above
-37.6% to fair value
ACCE score
68
out of 100
Analysts
81% buy
32 covering
P/E
30.5x
forward 24.1x
1-year return
+24.0%
Dividend yield
0.00%
Vertex Pharmaceuticals Incorporated Common Stock in four questions
Plain answers, details below
Free accounts get 5 full stock pages a month, including the four answers.
Overview
ACCE thesis
Vertex sells Trikafta, Symdeko and Alyftrek, its cystic fibrosis modulator franchise, which treats the underlying CFTR defect in roughly nine in ten patients and has made it the dominant player in CF care for years. The moat is the scale of that franchise, its long patent runway, and a 38.1% operating margin that funds a pipeline in pain, kidney disease and type 1 diabetes without needing outside capital. The near-term story is whether the CF franchise keeps expanding into younger and broader patient groups while the newer programs move toward late-stage readouts. At 24.1x forward earnings against 29.6x trailing, the market is pricing in continued earnings growth on 12.5% revenue growth and a 23.5% ROE. Worth a deeper look to test how durable the CF cash flows are against the pipeline timelines.